Numerous studies have shown that PD-L1 plays an important role in malignant melanoma, renal cell carcinoma, non-small cell lung cancer, and head and neck squamous cell carcinoma, which is both an important indicator indicating poor prognosis and an important target for clinical drug studies [9, 10]. This evidence concerns the gene CD274 and melanoma.